Product Description
LY3871801 is a solid dispersion suspension administered orally being developed by Eli Lilly. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05222399?term=LY-3871801&draw=2&rank=1)
Mechanisms of Action: RIPK1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Eli Lilly
Company Location: Eastern America
Company Founding Year: 1876
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Czech Republic, France, Germany, Hungary, India, Mexico, Poland, Slovakia, United Kingdom, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Arthritis, Rheumatoid
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2022-502994-40-00 |
2022-502994-40-00 | P2 |
Recruiting |
Arthritis, Rheumatoid |
2026-07-15 |
12% |
2025-05-02 |
Treatments |
NCT05848258 |
J3P-MC-FTAF | P2 |
Completed |
Arthritis, Rheumatoid |
2025-12-08 |
12% |
2026-05-23 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/04/2023 |
News Article |
Biopharmaceuticals Market Revenue to Reach USD 8,56,100 Million by 2030 |
|
02/16/2023 |
News Article |
Protein Inhibitors Global Market Report 2023 |
|
01/09/2023 |
News Article |
Rigel Pharmaceuticals Provides Business Update |
|
09/28/2022 |
News Article |
Biopharmaceutical Market Size Will Attain USD 853 Billion by 2030 growing at 11.3% CAGR - Exclusive Report by Acumen Research and Consulting |